Role of Repeat<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma

Kukar, Moshim; Alnaji, Raed M.; Jabi, Feraas; Platz, Timothy A.; Attwood, Kristopher; Nava, Hector; Ben-David, Kfır; Mattson, David; Salerno, Kilian E.; Malhotra, Usha; Kanehira, Kazunori; Gannon, James; Hochwald, Steven N.

doi:10.1001/jamasurg.2014.3867

Cited by 49 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-eight publications were left after checking the full texts. Six studies were out for not enough information to construct 2 × 2 contingency table (11)(12)(13)(14)(15)(16). For that the main purpose of the present study is to evaluate the therapeutic response of the primary tumor to NCRT, six studies in which pathological response criteria were consisted of lymph nodes or metastatic diseases regression assessment were excluded (17)(18)(19)(20)(21)(22).…”

Section: Resultsmentioning

confidence: 99%

The predictive value of¹⁸F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

Cong

Wang

Gao

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: We want to review the value of 18-fluoro-deoxy-glucose positron emission tomography for response prediction of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy. Methods: Studies were searched in Pubmed, Embase and Cochrane Library with specific search strategy. The published articles were included according to the criteria established in advance. The included studies were divided into two groups according to the time of the repeat positron emission tomography: during (Group A) or after neoadjuvant chemoradiotherapy (Group B). The studies that performed the repeat positron emission tomography after neoadjuvant chemoradiotherapy were graded Quality Assessment of Diagnostic Accuracy Studies. The pooled sensitivity, specificity and diagnostic odds ratio were obtained for both groups on the basis of no-existing of threshold effect. Results: Fifteen studies were included in the present study. The threshold effect did not exist in both groups. The pooled sensitivity, specificity and diagnostic odds ratio were 85%, 59%, 6.82 with 95% confidence interval 76-91%, 48-69%, 2.25-20.72 in Group A. The equivalent values were 67%, 69%, 6.34 with 95% confidence interval 60-73%, 63-74%, 2.08-19.34 in Group B. The pooled sensitivity was 90% in four studies that enrolled patients with esophageal squamous cell carcinoma merely in Group B. Conclusions: According to the present data, positron emission tomography should not be used routinely to guide treatment strategy in esophageal cancer patients. We speculated that positron emission tomography could be used as a tool to predict treatment response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

show abstract

Section: Resultsmentioning

confidence: 99%

The predictive value of¹⁸F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

Cong

Wang

Gao

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

show abstract

“…These findings could reflect that NT was in more advanced status. Also, the survival superiority of NT followed by surgery over prompt surgery could result from occult metastases undetected by PET-CT (11,15). We also attribute this finding to the survival superiority of NT followed by surgery over prompt surgery.…”

Section: Discussionmentioning

confidence: 79%

“…No definitive findings or established guidelines have been published for the evaluation of esophageal tumors (tumor) and regional LN using PET-CT in patients with esophageal cancer (2,7,8,10). In addition, it remains unclear whether PET-CT findings vary between patients treated with and without NT (2,11). The purpose of the present study is to clarify any variation in PET-CT findings between esophageal cancer patients treated with and without NT and to predict LN metastases for better prognosis.…”

Section: Introductionmentioning

confidence: 93%

A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer

2016

View full text Add to dashboard Cite

Background: No definitive findings or established guidelines have been published for the evaluation of esophageal tumors (tumor) and regional lymph nodes (LN) using positron emission tomography computed tomography (PET-CT) in patients with esophageal cancer. In addition, it remains unclear whether PET-CT findings vary between neoadjuvant (NT) and non-neoadjuvant (non-NT) therapy cases. Therefore, preoperative evaluation using PET-CT might provide unreliable information and influence the management plan for esophageal cancer. The purpose of the present study is to clarify the different findings of PET-CT between NT and non-NT in surgical esophageal cancer cases and to predict LN metastasis. Methods: We retrospectively reviewed the medical records of 192 consecutive cases that met this study's inclusion criteria from January 2009 to December 2014. All patients underwent curative and complete esophagectomy for intra-thoracic esophageal cancer at the department of thoracic and cardiovascular surgery in a single tertiary Korean hospital. We compiled and analyzed maximum standard uptake values (SUV max ) of tumor and LNs with other clinical information (chronic lung disease, history of previous other primary cancer, sex, pathological findings, NT, and other clinical data). values being equal, non-NT had significantly higher DFS and OS than NT (P=0.011, P=0.009, respectively), despite the absence of significant differences in pathological stage; (III) Tumor SUV max had a positive correlation with LN SUV max in both NT and non-NT (P=0.006, P<0.001, respectively); (IV) In NT, there were no diagnostic findings of LN metastases using SUV max . However, in non-NT, significant cutoff values for diagnosis of LN metastases using both tumor and LN SUV max were found (tumor SUV max cutoff value 4.9, P=0.008; LN SUV max cutoff value 2.5, P=0.045); (V) In NT, there was no significant difference in LN SUV max between pathologically negative and positive LNs. However, in non-NT, the LN SUV max of pathologically positive LNs was significantly higher than that of pathologically negative LNs (P=0.042); (VI) There were no significant differences in tumor and LN SUV max according to various factors, including chronic lung disease 785

show abstract

“…Kukar et al reported in 77 patients and noted that less than 45% SUV decrease was a risk factor for residual disease (25). Another study with 53 EAC patients reported that a decrease of >23.5% SUV resulted in the sensitivity and specificity for (21,23,28).…”

Section: Predicting Preoperative Chemoradiation Response By Pet-ctmentioning

confidence: 98%

Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma

et al. 2018

View full text Add to dashboard Cite

Preoperative therapy is the gold standard for esophageal or gastroesophageal junction adenocarcinoma. Positron emission tomography (PET) is not only essential for tumor staging, but changes in glucose consumption correspond with response to therapy and correlated with prognosis. Therefore, with further refinement, PET parameter can serve as a tool for personalized therapy. For instance, the Municon trials suggested the possibility of PET-response guided therapy for esophageal adenocarcinoma (EAC) patients, however there are limitations. New PET parameters such as total lesion glycolysis (TLG) or magnetic resonance imaging (MRI) may provide better response prediction. Furthermore, PET parameters combined with genomic profiling might enhance better treatment selection, prediction, and prognostication.Here, we summarized the current state of understanding and future possibilities.

show abstract

Role of Repeat¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma

Cited by 49 publications

References 30 publications

The predictive value of¹⁸F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

The predictive value of¹⁸F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer

Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma

Contact Info

Product

Resources

About

Role of Repeat18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma

Cited by 49 publications

References 30 publications

The predictive value of18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

The predictive value of18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer

Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma

Contact Info

Product

Resources

About

Role of Repeat¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma

The predictive value of¹⁸F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis

The predictive value of¹⁸F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis